{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:30:41Z","timestamp":1793374241906,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s10198-012-0443-2","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T12:35:25Z","timestamp":1359030925000},"page":"7-18","source":"Crossref","is-referenced-by-count":26,"title":["Health state utilities for skeletal-related events secondary to bone metastases"],"prefix":"10.1007","volume":"15","author":[{"given":"Louis S.","family":"Matza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Van Brunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Brazier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Currie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Palsgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,25]]},"reference":[{"issue":"8 Suppl","key":"443_CR1","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman, R.E.: Skeletal complications of malignancy. Cancer 80(8 Suppl), 1588\u20131594 (1997). doi: 10.1002\/(SICI)1097-0142(19971015)80","journal-title":"Cancer"},{"key":"443_CR2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/ar2169","volume":"9 Suppl 1","author":"MS Virk","year":"2007","unstructured":"Virk, M.S., Lieberman, J.R.: Tumor metastasis to bone. Arthritis Res Ther 9 Suppl 1, S5 (2007). doi: 10.1186\/ar2169","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"443_CR3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman, R.E.: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27(3), 165\u2013176 (2001)","journal-title":"Cancer Treat. Rev."},{"issue":"9768","key":"443_CR4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., Jiang, Q., Tadros, S., Dansey, R., Goessl, C.: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768), 813\u2013822 (2011). doi: 10.1016\/S0140-6736(10)62344-6","journal-title":"Lancet"},{"issue":"5","key":"443_CR5","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton, A., Theriault, R.L., Hortobagyi, G.N., Simeone, J., Knight, R.D., Mellars, K., Reitsma, D.J., Heffernan, M., Seaman, J.J.: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5), 1082\u20131090 (2000). doi: 10.1002\/(SICI)1097-0142(20000301)88","journal-title":"Cancer"},{"issue":"12","key":"443_CR6","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen, L.S., Gordon, D., Tchekmedyian, N.S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., De Souza, P., Zheng, M., Urbanowitz, G., Reitsma, D., Seaman, J.: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100(12), 2613\u20132621 (2004). doi: 10.1002\/cncr.20308","journal-title":"Cancer"},{"issue":"35","key":"443_CR7","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck, A.T., Lipton, A., Body, J.J., Steger, G.G., Tonkin, K., de Boer, R.H., Lichinitser, M., Fujiwara, Y., Yardley, D.A., Viniegra, M., Fan, M., Jiang, Q., Dansey, R., Jun, S., Braun, A.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28(35), 5132\u20135139 (2010). doi: 10.1200\/JCO.2010.29.7101","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"443_CR8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","volume":"111","author":"JJ Body","year":"2004","unstructured":"Body, J.J., Diel, I.J., Bell, R., Pecherstorfer, M., Lichinitser, M.R., Lazarev, A.F., Tripathy, D., Bergstrom, B.: Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111(3), 306\u2013312 (2004). doi: 10.1016\/j.pain.2004.07.011","journal-title":"Pain"},{"issue":"4","key":"443_CR9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","volume":"16","author":"KP Weinfurt","year":"2005","unstructured":"Weinfurt, K.P., Li, Y., Castel, L.D., Saad, F., Timbie, J.W., Glendenning, G.A., Schulman, K.A.: The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol. 16(4), 579\u2013584 (2005)","journal-title":"Ann. Oncol."},{"issue":"1","key":"443_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-6296(86)90020-2","volume":"5","author":"GW Torrance","year":"1986","unstructured":"Torrance, G.W.: Measurement of health state utilities for economic appraisal. J Health Econ 5(1), 1\u201330 (1986)","journal-title":"J Health Econ"},{"key":"443_CR11","volume-title":"Quality of Life and Pharmacoeconomics in Clinical Trials","author":"GW Torrance","year":"1996","unstructured":"Torrance, G.W.: Designing and conducting cost-utility analyses. In: Spilker, B. (ed.) Quality of Life and Pharmacoeconomics in Clinical Trials. Lippincott-Raven Publishers, Philadelphia (1996)"},{"key":"443_CR12","volume-title":"Effect of Cancer on Quality of Life","author":"D Feeny","year":"1991","unstructured":"Feeny, D., Barr, R.D., Furlong, W., Torrance, G.W., Weitzman, S.: Quality of life of the treatment process in pediatric oncology: an approach to measurement. In: Osaba, D. (ed.) Effect of Cancer on Quality of Life. CRC Press, Boca Raton (1991)"},{"issue":"6","key":"443_CR13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/0021-9681(87)90019-1","volume":"40","author":"GW Torrance","year":"1987","unstructured":"Torrance, G.W.: Utility approach to measuring health-related quality of life. J Chronic Dis 40(6), 593\u2013603 (1987)","journal-title":"J Chronic Dis"},{"issue":"2","key":"443_CR14","first-page":"99","volume":"2","author":"GW Torrance","year":"2002","unstructured":"Torrance, G.W., Furlong, W., Feeny, D.: Health utility estimation. Expert Rev Pharmacoeconomics Res 2(2), 99\u2013108 (2002)","journal-title":"Expert Rev Pharmacoeconomics Res"},{"issue":"3","key":"443_CR15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00019053-200624030-00007","volume":"24","author":"RJ Milne","year":"2006","unstructured":"Milne, R.J., Heaton-Brown, K.H., Hansen, P., Thomas, D., Harvey, V., Cubitt, A.: Quality-of-life valuations of advanced breast cancer by New Zealand women. Pharmacoeconomics 24(3), 281\u2013292 (2006)","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"443_CR16","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/01.ju.0000116777.94426.60","volume":"171","author":"SD Reed","year":"2004","unstructured":"Reed, S.D., Radeva, J.I., Glendenning, G.A., Saad, F., Schulman, K.A.: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J. Urol. 171(4), 1537\u20131542 (2004)","journal-title":"J. Urol."},{"issue":"12","key":"443_CR17","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00520-005-0828-1","volume":"13","author":"E Cock De","year":"2005","unstructured":"De Cock, E., Hutton, J., Canney, P., Body, J.J., Barrett-Lee, P., Neary, M.P., Lewis, G.: Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support. Care Cancer 13(12), 975\u2013986 (2005). doi: 10.1007\/s00520-005-0828-1","journal-title":"Support. Care Cancer"},{"issue":"4","key":"443_CR18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s005200050260","volume":"7","author":"G Dranitsaris","year":"1999","unstructured":"Dranitsaris, G., Hsu, T.: Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support. Care Cancer 7(4), 271\u2013279 (1999)","journal-title":"Support. Care Cancer"},{"issue":"1","key":"443_CR19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/bcr413","volume":"4","author":"JE Brown","year":"2002","unstructured":"Brown, J.E., Coleman, R.E.: The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res. 4(1), 24\u201329 (2002)","journal-title":"Breast Cancer Res."},{"issue":"7","key":"443_CR20","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.ejca.2008.11.013","volume":"45","author":"E Chow","year":"2009","unstructured":"Chow, E., Hird, A., Velikova, G., Johnson, C., Dewolf, L., Bezjak, A., Wu, J., Shafiq, J., Sezer, O., Kardamakis, D., Linden, Y.v.d., Ma, B., Castro, M., Arnalot, P.F., Ahmedzai, S., Clemons, M., Hoskin, P., Yee, A., Brundage, M., Bottomley, A.: The European organisation for research and treatment of cancer quality of life questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur. J. Cancer 45(7), 1146\u20131152 (2009)","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"443_CR21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1634\/theoncologist.11-3-227","volume":"11","author":"M Clemons","year":"2006","unstructured":"Clemons, M., Dranitsaris, G., Cole, D., Gainford, M.C.: Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. Oncologist 11(3), 227\u2013233 (2006)","journal-title":"Oncologist"},{"issue":"10","key":"443_CR22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.12968\/ijpn.2006.12.10.22118","volume":"12","author":"L Drudge-Coates","year":"2006","unstructured":"Drudge-Coates, L.: Skeletal complications and the use of bisphosphonates in metastatic prostate cancer. Int J Palliat Nurs 12(10), 462\u2013469 (2006)","journal-title":"Int J Palliat Nurs"},{"issue":"4","key":"443_CR23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10555-006-9025-z","volume":"25","author":"A Lin","year":"2006","unstructured":"Lin, A., Ray, M.E.: Targeted and systemic radiotherapy in the treatment of bone metastasis. Cancer Metastasis Rev. 25(4), 669\u2013675 (2006)","journal-title":"Cancer Metastasis Rev."},{"issue":"8","key":"443_CR24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy, G.R.: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2(8), 584\u2013593 (2002)","journal-title":"Nat. Rev. Cancer"},{"key":"443_CR25","volume-title":"Measuring and Valuing Health Benefits for Economic Evaluation","author":"JR Brazier","year":"2007","unstructured":"Brazier, J.R., Ratcliffe, J., Salomon, J.A., Tsuchiya, A.: Measuring and Valuing Health Benefits for Economic Evaluation. Oxford University Press, New York (2007)"},{"issue":"2","key":"443_CR26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N","volume":"5","author":"P Dolan","year":"1996","unstructured":"Dolan, P., Gudex, C., Kind, P., Williams, A.: The time trade-off method: results from a general population study. Health Econ. 5(2), 141\u2013154 (1996). doi: 10.1002\/(SICI)1099-1050(199603)5","journal-title":"Health Econ."},{"issue":"7","key":"443_CR27","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s11136-007-9226-0","volume":"16","author":"LS Matza","year":"2007","unstructured":"Matza, L.S., Boye, K.S., Yurgin, N., Brewster-Jordan, J., Mannix, S., Shorr, J.M., Barber, B.L.: Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual. Life Res. 16(7), 1251\u20131265 (2007). doi: 10.1007\/s11136-007-9226-0","journal-title":"Qual. Life Res."},{"issue":"3","key":"443_CR28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10198-010-0224-8","volume":"12","author":"KS Boye","year":"2011","unstructured":"Boye, K.S., Matza, L.S., Walter, K.N., Van Brunt, K., Palsgrove, A.C., Tynan, A.: Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 12(3), 219\u2013230 (2011). doi: 10.1007\/s10198-010-0224-8","journal-title":"Eur J Health Econ"},{"issue":"6","key":"443_CR29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware Jr, J.E., Sherbourne, C.D.: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30(6), 473\u2013483 (1992)","journal-title":"Med. Care"},{"key":"443_CR30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/oso\/9780198527695.003.0025","volume-title":"Assessing Quality of Life in Clinical Trials","author":"D Feeny","year":"2005","unstructured":"Feeny, D.: Preference-based measures: utility and quality-adjusted life years. In: Fayers, P., Hays, R. (eds.) Assessing Quality of Life in Clinical Trials, pp. 405\u2013431. Oxford University Press, New York (2005)"},{"key":"443_CR31","first-page":"S8","volume":"3 Suppl","author":"GW Torrance","year":"1997","unstructured":"Torrance, G.W.: Preferences for health outcomes and cost-utility analysis. Am. J. Manag. care 3 Suppl, S8\u201320 (1997)","journal-title":"Am. J. Manag. care"},{"issue":"4","key":"443_CR32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1017\/S0266462300008461","volume":"5","author":"GW Torrance","year":"1989","unstructured":"Torrance, G.W., Feeny, D.: Utilities and quality-adjusted life years. Int. J. Technol. Assess. Health Care 5(4), 559\u2013575 (1989)","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"443_CR33","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"1988","unstructured":"Cohen, J.: Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Lawrence Erlbaum Associates, Hillsdale (1988)","edition":"2"},{"key":"443_CR34","first-page":"788","volume-title":"The Oxford Handbook of Health Economics","author":"D Rowen","year":"2011","unstructured":"Rowen, D., Brazier, J.: Health utility measurement. In: Glied, S., Smith, P.C. (eds.) The Oxford Handbook of Health Economics, pp. 788\u2013813. Oxford University Press, New York (2011)"},{"issue":"3","key":"443_CR35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00435221","volume":"2","author":"J Brazier","year":"1993","unstructured":"Brazier, J., Jones, N., Kind, P.: Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual. Life Res. 2(3), 169\u2013180 (1993)","journal-title":"Qual. Life Res."},{"issue":"3","key":"443_CR36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/135581969900400310","volume":"4","author":"J Brazier","year":"1999","unstructured":"Brazier, J., Deverill, M., Green, C.: A review of the use of health status measures in economic evaluation. J. Health Serv. Res. Policy 4(3), 174 (1999)","journal-title":"J. Health Serv. Res. Policy"},{"issue":"12","key":"443_CR37","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s00134-004-2471-6","volume":"30","author":"A Kaarlola","year":"2004","unstructured":"Kaarlola, A., Pettila, V., Kekki, P.: Performance of two measures of general health-related quality of life, the EQ-5D and the RAND-36 among critically ill patients. Intensive Care Med. 30(12), 2245\u20132252 (2004). doi: 10.1007\/s00134-004-2471-6","journal-title":"Intensive Care Med."},{"issue":"4","key":"443_CR38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00148365-200504040-00004","volume":"4","author":"K Stein","year":"2005","unstructured":"Stein, K., Fry, A., Round, A., Milne, R., Brazier, J.: What value health? A review of health state values used in early technology assessments for NICE. Appl. Health Econ. Health Policy 4(4), 219\u2013228 (2005)","journal-title":"Appl. Health Econ. Health Policy"},{"key":"443_CR39","volume-title":"What are Health Utilities?","author":"K Tolley","year":"2009","unstructured":"Tolley, K.: What are Health Utilities? Hayward Medical Communications, London (2009)"},{"issue":"9","key":"443_CR40","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hec.866","volume":"13","author":"J Brazier","year":"2004","unstructured":"Brazier, J., Roberts, J., Tsuchiya, A., Busschbach, J.: A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 13(9), 873\u2013884 (2004). doi: 10.1002\/hec.866","journal-title":"Health Econ."},{"issue":"7","key":"443_CR41","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s11136-008-9368-8","volume":"17","author":"PL Ferreira","year":"2008","unstructured":"Ferreira, P.L., Ferreira, L.N., Pereira, L.N.: How consistent are health utility values? Qual. Life Res. 17(7), 1031\u20131042 (2008)","journal-title":"Qual. Life Res."},{"issue":"8","key":"443_CR42","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/11588250-000000000-00000","volume":"29","author":"M Garau","year":"2011","unstructured":"Garau, M., Shah, K.K., Mason, A.R., Wang, Q., Towse, A., Drummond, M.F.: Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics 29(8), 673\u2013685 (2011). doi: 10.2165\/11588250-000000000-00000","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"443_CR43","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00019053-200826090-00007","volume":"26","author":"J Brazier","year":"2008","unstructured":"Brazier, J.: Valuing health States for use in cost-effectiveness analysis. Pharmacoeconomics 26(9), 769\u2013779 (2008)","journal-title":"Pharmacoeconomics"},{"key":"443_CR44","unstructured":"NICE: Guide to the methods of technology appraisal. In. National Institute for Health and Clinical Excellence, London, (2008)"},{"key":"443_CR45","unstructured":"PBAC: Guidelines for preparing submissions to PBAC, Version 4.3.2. In. Pharmaceutical Benefits Advisory Committee, (2008)"},{"issue":"11","key":"443_CR46","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35(11), 1095\u20131108 (1997)","journal-title":"Med. Care"},{"key":"443_CR47","doi-asserted-by":"crossref","unstructured":"Fallowfield, L., Cleeland, C.S., Body, J.J., Stopeck, A., von Moos, R., Patrick, D.L., Clemons, M., Tonkin, K., Masuda, N., Lipton, A., De Boer, R., Salvagni, S., Tosello, O.C., Ying, W., Braun, A., Cong, Z.: Pain severity and analgesic use associated with Skeletal-related events in patients with advanced breast cancer and bone metastases. Cancer Res (2011: 71 (24 Suppl): Abstract nr P4-13-01)","DOI":"10.1158\/0008-5472.SABCS11-P4-13-01"},{"issue":"20 Pt 2","key":"443_CR48","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman, R.E.: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12(20 Pt 2), 6243s\u20136249s (2006). doi: 10.1158\/1078-0432.CCR-06-0931","journal-title":"Clin. Cancer Res."},{"key":"443_CR49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1477-7525-3-17","volume":"3","author":"GM Lee","year":"2005","unstructured":"Lee, G.M., Salomon, J.A., LeBaron, C.W., Lieu, T.A.: Health-state valuations for pertussis: methods for valuing short-term health states. Health Qual Life Outcomes 3, 17 (2005). doi: 10.1186\/1477-7525-3-17","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"443_CR50","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/0895-4356(95)00011-R","volume":"48","author":"A Stiggelbout","year":"1995","unstructured":"Stiggelbout, A., Kiebert, G., Kievit, J., Leer, J., Habbema, J., De Haes, J.: The \u201cutility\u201d of the time trade-off method in cancer patients: feasibility and proportional trade-off. J. Clin. Epidemiol. 48(10), 1207\u20131214 (1995)","journal-title":"J. Clin. Epidemiol."},{"issue":"6","key":"443_CR51","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/hec.1074","volume":"15","author":"J Brazier","year":"2006","unstructured":"Brazier, J., Dolan, P., Karampela, K., Towers, I.: Does the whole equal the sum of the parts? Patient-assigned utility scores for IBS-related health states and profiles. Health Econ. 15(6), 543\u2013551 (2006). doi: 10.1002\/hec.1074","journal-title":"Health Econ."}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-012-0443-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T04:48:13Z","timestamp":1714884493000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-012-0443-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,25]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["443"],"URL":"https:\/\/doi.org\/10.1007\/s10198-012-0443-2","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,25]]}}}